SEC Company Response from PURPLE BIOTECH LTD. (PPBT) (CIK 0001614744) (PPBT) — Aug 6, 2018
PURPLE BIOTECH LTD. (PPBT) (CIK 0001614744)
Date: Aug. 6, 2018 · CIK: 0001614744 · Accession: 0001213900-18-010297
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-226195
Letter
Kitov Pharma Ltd.
One Azrieli Center, Round Tower
Menachem Begin Road
Tel Aviv, 6701101, Israel
August 6, 2018
By EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street N.E.
Washington, D.C. 20549
RE: Kitov Pharma Ltd.
Registration Statement on Form F-3
Originally filed July 16, 2018
File No. 333-226195
Ladies and Gentlemen:
Pursuant to Rule 461 of the Rules and Regulations of the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended, Kitov Pharma Ltd. (the “Company”) hereby requests acceleration of the effective date of the above-mentioned Registration Statement on Form F-3 (the “Registration Statement”) to 5:00 p.m., Eastern Time on August 8, 2018, or as soon thereafter as practicable.
Should any member of the staff of the U.S. Securities and Exchange Commission have any questions or comments with respect to this request, please contact our counsel, Haynes and Boone, LLP, attention: Rick A. Werner, Esq. at (212) 659-4974.
Very
truly yours,
Kitov
Pharma Ltd.
Show Raw Text
CORRESP
1
filename1.htm
Kitov
Pharma Ltd.
One Azrieli Center, Round Tower
132
Menachem Begin Road
Tel
Aviv, 6701101, Israel
August
6, 2018
By
EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street N.E.
Washington,
D.C. 20549
RE:
Kitov
Pharma Ltd.
Registration Statement on Form F-3
Originally filed July 16, 2018
File
No. 333-226195
Ladies
and Gentlemen:
Pursuant
to Rule 461 of the Rules and Regulations of the Securities and Exchange Commission (the “Commission”) under
the Securities Act of 1933, as amended, Kitov Pharma Ltd. (the “Company”) hereby requests acceleration of the
effective date of the above-mentioned Registration Statement on Form F-3 (the “Registration Statement”) to
5:00 p.m., Eastern Time on August 8, 2018, or as soon thereafter as practicable.
Should
any member of the staff of the U.S. Securities and Exchange Commission have any questions or comments with respect to this request,
please contact our counsel, Haynes and Boone, LLP, attention: Rick A. Werner, Esq. at (212) 659-4974.
Very
truly yours,
Kitov
Pharma Ltd.
By:
/s/ Isaac Israel
Isaac Israel
Chief Executive Officer